Physician profile
Jennifer E Anthony
NPI 1811565286
$9,055.89
in general payments reported to CMS, 2019-2025
33 companies · $2,311 in 2025
The $2,311 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $371 · 2022: $1,803 · 2023: $2,045 · 2024: $2,526 · 2025: $2,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,798 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,798.25 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,932.43 | 2021-2025 | |
| Janssen Biotech, INC. | $1,219.11 | 2021-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $650.37 | 2022-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $563.86 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $363.89 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $320.96 | 2023-2025 | Vowst, Zenpep |
| Qol Medical, LLC | $305.04 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $270.04 | 2023-2024 | Zeposia |
| Lilly USA, LLC | $260.57 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $257.04 | 2021-2024 | Dificid, Zinplava |
| Phathom Pharmaceuticals, INC. | $234.99 | 2024-2025 | Voquezna |
| Genzyme Corporation | $227.04 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $190.59 | 2022-2023 | |
| Ardelyx, INC. | $187.80 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $147.38 | 2022-2024 | Dupixent |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $132.78 | 2021-2024 | Rebyota, Clenpiq |
| Braintree Laboratories, INC. | $132.32 | 2022-2025 | Suflave, Sutab |
| Evoke Pharma, INC. | $101.62 | 2021-2024 | Gimoti |
| Intercept Pharmaceuticals, INC. | $80.79 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.57 | 2023-2024 | Cyltezo |
| Daiichi Sankyo INC. | $56.12 | 2021-2023 | Injectafer |
| Ascendis Pharma Endocrinology INC | $55.00 | 2025 | Yorvipath |
| Ironwood Pharmaceuticals, INC | $53.41 | 2022-2024 | |
| Novo Nordisk INC | $39.02 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $35.61 | 2024 | Iqirvo |
| Amgen INC. | $34.60 | 2023-2025 | Amjevita, Uplizna |
| Redhill Biopharma INC. | $31.49 | 2021-2022 | |
| Mylan Institutional INC. | $24.37 | 2023 | Hulio |
| Organon LLC | $18.76 | 2023-2024 | Hadlima |
| Alexion Pharmaceuticals, INC. | $17.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.77 | 2025 | Xifaxan |
| Celltrion USA INC. | $16.34 | 2024 | Zymfentra |
| Gilead Sciences, INC. | $15.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.